Hong-Hui Yang1, Yan Chen1, Chuan-Yu Gao1, Zhen-Tian Cui2, Jian-Min Yao2. 1. Department of Cardiology, Zhengzhou University People's Hospital, Zhengzhou, China. 2. Cardiovascular Surgery, General Hospital of Beijing Military Region, Chinese People's Liberation Army, Beijing, China.
Abstract
OBJECTIVE: This study explored the protective effects of the microRNA-126 (miR-126)-mediated PI3K/Akt/eNOS signaling pathway on human cardiac microvascular endothelial cells (HCMECs) against hypoxia/reoxygenation (H/R)-induced injury and the inflammatory response. METHODS: Untreated HCMECs were selected for the control group. After H/R treatment and cell transfection, the HCMECs were assigned to the H/R, miR-126 mimic, mimic-negative control (NC), miR-126 inhibitor, inhibitor-NC, wortmannin (an inhibitor of PI3K) and miR-126 mimic + wortmannin groups. Super oxide dismutase (SOD), nitric oxide (NO), vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) were measured utilizing commercial kits. Quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were performed to detect miR-126 expression and the mRNA and protein expression of inflammatory factors. Western blotting was used to determine the expression of key members in the PI3K/Akt/eNOS signaling pathway. ACCK-8 assay and flow cytometry were employed to examine cell proliferation and apoptosis, respectively. The angiogenic ability in each group was detected by the lumen formation test. RESULTS: Compared to the control group, p/t-PI3K, p/t-Akt and p/t-eNOS expression, NO, VEGF and SOD levels, cell proliferation and in vitro lumen formation ability were decreased, while the ROS content, interleukin (IL)-6, IL-10 and tumor necrosis factor (TNF)-α expression and cell apoptosis were significantly increased in the H/R, mimic-NC, miR-126 inhibitor, inhibitor-NC, wortmannin and miR-126 mimic + wortmannin groups. Additionally, in comparison with the H/R group, the miR-126 mimic group had elevated p/t-PI3K, p/t-Akt and p/t-eNOS expression, increased NO, VEGF and SOD contents, and strengthened cell proliferation and lumen formation abilities but also exhibited decreased ROS content, reduced IL-6, IL-10 and TNF-α expressions, and weakened cell apoptosis, while the miR-126 inhibitor and wortmannin group exhibited the opposite results. Furthermore, decreased p/t-PI3K, p/t-Akt and p/t-eNOS expressions, decreased NO, VEGF and SOD contents, cell proliferation and lumen formation abilities, as well as increased ROS content, increased IL-6, IL-10 and TNF-α expression, and increased cell apoptosis were observed in the miR-126 mimic + wortmannin group compared to themiR-126 mimic group. CONCLUSIONS: These findings indicated that miR-126 protects HCMECs from H/R-induced injury and inflammatory response by activating the PI3K/Akt/ eNOS signaling pathway.
OBJECTIVE: This study explored the protective effects of the microRNA-126 (miR-126)-mediated PI3K/Akt/eNOS signaling pathway on human cardiac microvascular endothelial cells (HCMECs) against hypoxia/reoxygenation (H/R)-induced injury and the inflammatory response. METHODS: Untreated HCMECs were selected for the control group. After H/R treatment and cell transfection, the HCMECs were assigned to the H/R, miR-126 mimic, mimic-negative control (NC), miR-126 inhibitor, inhibitor-NC, wortmannin (an inhibitor of PI3K) and miR-126 mimic + wortmannin groups. Super oxide dismutase (SOD), nitric oxide (NO), vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS) were measured utilizing commercial kits. Quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were performed to detect miR-126 expression and the mRNA and protein expression of inflammatory factors. Western blotting was used to determine the expression of key members in the PI3K/Akt/eNOS signaling pathway. ACCK-8 assay and flow cytometry were employed to examine cell proliferation and apoptosis, respectively. The angiogenic ability in each group was detected by the lumen formation test. RESULTS: Compared to the control group, p/t-PI3K, p/t-Akt and p/t-eNOS expression, NO, VEGF and SOD levels, cell proliferation and in vitro lumen formation ability were decreased, while the ROS content, interleukin (IL)-6, IL-10 and tumor necrosis factor (TNF)-α expression and cell apoptosis were significantly increased in the H/R, mimic-NC, miR-126 inhibitor, inhibitor-NC, wortmannin and miR-126 mimic + wortmannin groups. Additionally, in comparison with the H/R group, the miR-126 mimic group had elevated p/t-PI3K, p/t-Akt and p/t-eNOS expression, increased NO, VEGF and SOD contents, and strengthened cell proliferation and lumen formation abilities but also exhibited decreased ROS content, reduced IL-6, IL-10 and TNF-α expressions, and weakened cell apoptosis, while the miR-126 inhibitor and wortmannin group exhibited the opposite results. Furthermore, decreased p/t-PI3K, p/t-Akt and p/t-eNOS expressions, decreased NO, VEGF and SOD contents, cell proliferation and lumen formation abilities, as well as increased ROS content, increased IL-6, IL-10 and TNF-α expression, and increased cell apoptosis were observed in the miR-126 mimic + wortmannin group compared to themiR-126 mimic group. CONCLUSIONS: These findings indicated that miR-126 protects HCMECs from H/R-induced injury and inflammatory response by activating the PI3K/Akt/ eNOS signaling pathway.
Authors: L Madden Brewster; Vinicius P Garcia; Ma'ayan V Levy; Kelly A Stockelman; Anabel Goulding; Noah M DeSouza; Jared J Greiner; Jamie G Hijmans; Christopher A DeSouza Journal: J Appl Physiol (1985) Date: 2020-04-23
Authors: Basak Icli; Winona Wu; Denizhan Ozdemir; Hao Li; Henry S Cheng; Stefan Haemmig; Xin Liu; Giorgio Giatsidis; Seyma Nazli Avci; Nathan Lee; Raphael Boesch Guimaraes; Andre Manica; Julio F Marchini; Stein Erik Rynning; Ivar Risnes; Ivana Hollan; Kevin Croce; Xianbin Yang; Dennis P Orgill; Mark W Feinberg Journal: Arterioscler Thromb Vasc Biol Date: 2019-05-16 Impact factor: 8.311
Authors: Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini Journal: J Cancer Res Clin Oncol Date: 2019-01-30 Impact factor: 4.553
Authors: L Madden Brewster; Anthony R Bain; Vinicius P Garcia; Hannah K Fandl; Rachel Stone; Noah M DeSouza; Jared J Greiner; Michael M Tymko; Gustavo A Vizcardo-Galindo; Romulo J Figueroa-Mujica; Francisco C Villafuerte; Philip N Ainslie; Christopher A DeSouza Journal: Am J Physiol Heart Circ Physiol Date: 2021-03-12 Impact factor: 4.733